Residency · Residency · Internal Medicine

Hypertension Management in the Outpatient Setting

Start here

Alright team, let’s talk hypertension. You're exhausted, I get it. The intern year feels like a never-ending sprint, but hypertension management is one of those bread-and-butter skills you’ll use every single day of your career. Imagine Mrs. Henderson, a sweet 72-year-old, sitting in your clinic. Her blood pressure (BP) just came back at 145/88 mmHg. Your first instinct might be to reach for a prescription pad, right? But hold on. Before you even think about starting a lifelong medication, your priority, always, is to confirm that diagnosis. One elevated reading in the clinic, especially after rushing to get there, isn't enough. We need to rule out "white-coat hypertension" – where the BP is high only in a clinical setting. Get her set up with a home blood pressure monitoring (HBPM) system, teaching her how to take readings properly (seated, arm supported at heart level, quiet for five minutes beforehand). If her home readings are consistently elevated, say an average over a week is 135/85 mmHg, then we know we have actual hypertension.

Now that Mrs. Henderson’s hypertension is confirmed, what's next? You wouldn't just throw drugs at her without thinking about the whole person. First, we tackle lifestyle. She loves salty snacks, so a discussion about dietary approaches to stop hypertension (DASH) and sodium restriction is crucial. Does she walk? Encourage 150 minutes of moderate exercise a week. These non-pharmacologic interventions can make a huge difference, often reducing systolic BP by 5-10 mmHg, sometimes enough to avoid medication or reduce the number of drugs needed. Only once these foundations are laid, and if her BP remains above goal, do we think about pharmacotherapy.

For Mrs. Henderson, without any specific comorbidities like diabetes or chronic kidney disease, a good starting point would be a thiazide-type diuretic, like chlorthalidone, or a calcium channel blocker. Remember, not all diuretics are created equal; chlorthalidone has better evidence for cardiovascular outcomes than hydrochlorothiazide. The goal isn't just to lower the number, but to protect her heart and kidneys for years to come. It’s about building a comprehensive plan, not just reacting to a single measurement.

Introduction

Hypertension affects nearly half of all US adults and remains the single largest modifiable risk factor for cardiovascular disease, stroke, and chronic kidney disease. The 2017 ACC/AHA guidelines redefined hypertension as blood pressure at or above 130/80 mmHg, substantially expanding the population requiring intervention. Internal medicine residents must master accurate measurement, risk stratification, and individualized pharmacotherapy.

Blood Pressure Measurement

Proper Technique

• Seated with back supported, feet flat on the floor, arm supported at heart level
• Appropriate cuff size: bladder encircling at least 80% of the upper arm circumference
• No caffeine, exercise, or smoking for 30 minutes prior
• Allow 5 minutes of quiet rest before measurement
• Average of 2-3 readings taken 1-2 minutes apart

Out-of-Office Measurement

• Ambulatory blood pressure monitoring (ABPM): gold standard for confirming hypertension and detecting white-coat or masked hypertension
• Home blood pressure monitoring (HBPM): morning and evening readings over 7 days; discard first day, average remaining values
• White-coat hypertension (elevated office BP, normal out-of-office): prevalence 15-30%; associated with intermediate cardiovascular risk
• Masked hypertension (normal office BP, elevated out-of-office): prevalence 10-15%; carries risk similar to sustained hypertension

Classification (2017 ACC/AHA)

Secondary Hypertension Screening

• Consider when onset is before age 30, resistant hypertension, abrupt worsening, or suggestive clinical features
• Primary aldosteronism: aldosterone-to-renin ratio (most common secondary cause)
• Renovascular disease: renal artery duplex ultrasound or CT angiography
• Pheochromocytoma: plasma free metanephrines
• Obstructive sleep apnea: STOP-BANG questionnaire, polysomnography
• Cushing syndrome: overnight dexamethasone suppression test or 24-hour urine cortisol
• Thyroid disease: TSH

Nonpharmacologic Interventions

• DASH diet: rich in fruits, vegetables, whole grains, low-fat dairy; reduces SBP by 8-14 mmHg
• Sodium restriction: target < 1500 mg/day; reduces SBP by 5-6 mmHg
• Aerobic exercise: 150 minutes/week moderate intensity; reduces SBP by 5-8 mmHg
• Weight loss: 1 mmHg reduction per kg lost
• Alcohol moderation: limit to 1 drink/day (women), 2 drinks/day (men)
• Potassium supplementation: 3500-5000 mg/day from dietary sources

Pharmacotherapy

First-Line Agents

• ACE inhibitors / ARBs: preferred in diabetes, CKD with proteinuria, heart failure with reduced ejection fraction
• Calcium channel blockers (amlodipine, nifedipine): effective across demographics; preferred in Black patients as monotherapy
• Thiazide/thiazide-like diuretics (chlorthalidone, indapamide): chlorthalidone preferred over HCTZ (longer half-life, stronger evidence)

Special Populations

• Black patients: initiate with CCB or thiazide; dual therapy often needed early
• CKD with proteinuria: ACEi or ARB mandatory; switch to loop diuretic if eGFR < 30
• Heart failure (HFrEF): ACEi/ARB (or ARNI), beta-blocker, MRA, and diuretic
• Pregnancy: labetalol, nifedipine, or methyldopa; avoid ACEi/ARB (teratogenic)
• Post-stroke: ACEi + thiazide combination (PROGRESS trial)

Resistant Hypertension

• Defined as BP above goal despite 3 optimally dosed agents including a diuretic
• Confirm adherence (pill counts, liquid chromatography-mass spectrometry)
• Add spironolactone 25-50 mg daily (PATHWAY-2 trial): most effective fourth-line agent
• Rule out secondary causes and optimize diuretic therapy

Blood Pressure Targets

• General population: < 130/80 mmHg (ACC/AHA 2017)
• SPRINT trial: intensive target (SBP < 120) reduced major cardiovascular events by 25% and all-cause mortality by 27%
• Elderly (>= 65 years): individualize; SPRINT included ambulatory patients >= 75 and showed benefit
• Diabetes: < 130/80 mmHg; evidence strongest for SBP < 130 (ACCORD BP showed stroke benefit)

Follow-Up and Monitoring

• Recheck BP at 1-month intervals after initiating or adjusting therapy
• Monitor electrolytes and creatinine within 2-4 weeks of starting ACEi/ARB or diuretic
• Once at goal, follow-up every 3-6 months
• Assess for medication side effects, adherence barriers, and lifestyle modifications at each visit

Key Clinical Pearls

• Always confirm the diagnosis with out-of-office measurements before initiating lifelong pharmacotherapy
• Chlorthalidone is preferred over HCTZ based on superior 24-hour BP lowering and cardiovascular outcome data
• Spironolactone is the most effective add-on agent for resistant hypertension
• Single-pill combinations improve adherence and should be considered early, especially in Stage 2 hypertension

References

1. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA Guideline for Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension. 2018;71(6):e13-e115.
2. SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373(22):2103-2116.
3. Williams B, MacDonald TM, Morant S, et al. Spironolactone versus Placebo, Bisoprolol, and Doxazosin to Determine the Optimal Treatment for Drug-Resistant Hypertension (PATHWAY-2). Lancet. 2015;386(10008):2059-2068.
4. Muntner P, Shimbo D, Carey RM, et al. Measurement of Blood Pressure in Humans: A Scientific Statement from the AHA. Hypertension. 2019;73(5):e35-e66.

For the intern

If you're called at 3am about hypertension, focus on hypertensive emergencies: BP ≥180/120 with end-organ damage (acute stroke, MI, pulmonary edema, encephalopathy). These require ICU admission and IV medications. Asymptomatic severe hypertension (urgency) can wait until morning—do not give sublingual nifedipine or send patients to the ED reflexively. Most outpatient hypertension decisions—medication initiation, dose titration, lifestyle counseling—are never urgent overnight. Confirm the reading is accurate (proper cuff size, patient position), review home readings if available, and schedule outpatient follow-up within days to weeks depending on severity.

Common pitfalls

• Starting medication based on a single office reading: Always confirm with out-of-office measurements (home monitoring or ambulatory monitoring) to avoid treating white-coat hypertension unnecessarily.

• Using hydrochlorothiazide instead of chlorthalidone: Chlorthalidone has superior 24-hour blood pressure control and stronger cardiovascular outcome data, though electrolyte monitoring is essential.

• Forgetting to check for secondary causes in young patients: New-onset hypertension before age 30, resistant hypertension, or sudden worsening should trigger screening for primary aldosteronism, renovascular disease, or obstructive sleep apnea.

• Under-treating Black patients: Monotherapy is often inadequate; initiate combination therapy early with a calcium channel blocker plus thiazide or ACE inhibitor/ARB depending on comorbidities.

Make it stick

Imagine Mrs. Smith, 62, presents with a BP of 150/90 mmHg in clinic. Instead of immediately prescribing medication, you recall the lecture. You politely ask her if she’s had caffeine recently and instruct her on proper home blood pressure monitoring (HBPM) for a week. She returns with HBPM readings averaging 125/78 mmHg. This isn't white-coat hypertension, but masked hypertension; her BP is consistently elevated at home but normal in the office. You confidently diagnose Stage 1 hypertension and start lifestyle modifications, avoiding unnecessary pharmacotherapy. This patient-centered approach ensures accurate diagnosis and appropriate management.

If you remember one thing

Always confirm hypertension with out-of-office blood pressure measurements before initiating lifelong medication. When choosing a diuretic, prefer chlorthalidone over hydrochlorothiazide due to its superior efficacy and longer half-life.

Read this lecture as Markdown